Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1835 results
February 2015
-
Press Release
Novartis' heart failure medicine LCZ696 granted FDA priority review
Decision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8 months Filing is based on results from the landmark PARADIGM-HF study[1] … -
Press Release
Alcon receives FDA approval of Pazeo(TM) Solution for ocular allergy itch relief
US Food and Drug Administration grants approval of Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7% for sale in the United States Developed with efficacy data at 24 hours, post dose…
January 2015
-
Press Release
Novartis announces study in NEJM showing Jakavi® was superior to standard therapy in rare blood cancer polycythemia vera
Jakavi® (ruxolitinib) treatment resulted in durable hematocrit control, spleen size reduction and symptom relief for patients with uncontrolled polycythemia vera[1] Polycythemia vera (PV) is… -
Press Release
Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses
Net sales grew in FY 2014, with strong core[1] margin expansion Net sales increased 1% (+3% cc[1])[2] to USD 58.0 billion in FY (Q4: -2%, +4% cc) Operating income grew 1% (+7% cc) to USD 10.7… -
Press Release
Novartis a enregistré en 2014 une forte augmentation de ses ventes, sa marge et progrès de son pipeline; la transformation du portefeuille concentrera l'entreprise sur ses principales activités
Hausse du chiffre d'affaires net en 2014, avec une forte augmentation de la marge core[1] Hausse du chiffre d'affaires net de 1% (+3% tcc[1])[2] à USD 58,0 milliards en 2014 (-2%, +4% tcc au T4)… -
Press Release
Novartis erzielt 2014 solide Umsatzsteigerungen, höhere Margen und Fortschritte in der Pipeline; mit der Umgestaltung des Portfolios fokussiert sich das Unternehmen auf führende Geschäftsbereiche
Wachstum des Nettoumsatzes im Jahr 2014 - mit starker Erhöhung der Kerngewinnmarge[1] Der Nettoumsatz steigt 2014 um 1% (+3% kWk[1])[2] auf USD 58,0 Milliarden (4. Quartal: -2%, +4% kWk) Das… -
Press Release
Novartis Bexsero® vaccine approved by FDA for the prevention of meningitis B, a leading cause of bacterial meningitis in the US
With today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide Bexsero's two-dose regimen offers a flexible… -
Press Release
Novartis drug Jakavi® recommended by CHMP for EU approval to treat adults with rare blood cancer polycythemia vera
Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack[1] Clinical data show Jakavi® (… -
Press Release
Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients
Offering a new treatment option for patients, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A[1],[2] Phase III data demonstrated… -
Press Release
Novartis Cosentyx(TM) is the first IL-17 inhibitor to receive EU approval for first-line treatment of moderate-to-severe psoriasis patients
Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects[1]; all other… -
Press Release
Novartis Pharmaceuticals announces a joint investment company with Qualcomm, leading innovation in digital medicines for physicians and patients
Novartis establishing a joint investment company with Qualcomm Ventures, the venture investment group of Qualcomm Incorporated, of up to USD 100 million to support early stage companies with… -
Press Release
Novartis announces robust Phase III results for QVA149 and NVA237 and submits regulatory applications to US FDA
Pivotal Phase III results for QVA149 and NVA237 met their primary endpoints and significantly improved lung function in COPD patients[1-5] US trials for QVA149 demonstrated significant…